1. Articles from Jose Solorio

    1-1 of 1
    1. Synergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene - Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

      Synergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene - Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

      A new movement in Synergy Pharmaceuticals ( SGYP ) is quickly gaining traction as more than 4.7 million shares have already been pledged in less than 10 hours to support an activist investor to take control of the company. This large group of 72 shareholders is asking fellow shareholders to pledge support for an activist campaign in the company. They are asking both Carl Icahn and Bill Ackman to get on board...

      Read Full Article
    1-1 of 1
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics in the News

    1. (1 articles) Bill Ackman
    2. (1 articles) CFO
    3. (1 articles) Carl Icahn
    4. (1 articles) Nasdaq
    5. (1 articles) Takeda
    6. (1 articles) Investors
    7. (1 articles) Activist Investors
    8. (1 articles) stock options
    9. (1 articles) stake
    10. (1 articles) risk
    11. (1 articles) Chairman
    12. (1 articles) Diversity
    13. (1 articles) Board Diversity
  3. Popular Articles

  4. Picture Gallery

    Synergy Pharmaceuticals Investors Ask Ackman And Icahn To Intervene - Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) 'You are messing with the wrong guy': The CEO of Cleveland-Cliffs Eviscerates Goldman Sachs analyst and short sellers (CLF) Sears is Reportedly Betting on a Lifeline From its Controversial Former CEO to Keep it From Liquidating in the Next Few Weeks It's Too Soon to Say P&G Turned the Tide Nestle Is Working With Advisers to Review Skin-Health Unit Ford Foundation Appoints Cisco CEO Chuck Robbins to its Board of Trustees Helios and Matheson Hires a Second Proxy Advisor StarKist Admits Fixing Tuna Prices, Faces $100 Million Collusion Fine Battle Between Campbell and Third Point Heats Up, No Concessions on the Table Campbell Soup CEO Sees No Room for Concessions to Third Point Cardinal Health Faces Pressure to Rework Executive Pay to Reflect Any Opioid Settlements 'Change the Board': Hedge-Fund Billionaire Dan Loeb Lays out his Plan to Turn Around Campbell Soup